|
1
|
WHO-EORTC classification for cutaneous lymphomas.
|
Blood
|
2005
|
12.14
|
|
2
|
Application of a filtration- and isolation-by-size technique for the detection of circulating tumor cells in cutaneous melanoma.
|
J Invest Dermatol
|
2010
|
3.26
|
|
3
|
Cutaneous side-effects of kinase inhibitors and blocking antibodies.
|
Lancet Oncol
|
2005
|
2.85
|
|
4
|
Subcutaneous panniculitis-like T-cell lymphoma: definition, classification, and prognostic factors: an EORTC Cutaneous Lymphoma Group Study of 83 cases.
|
Blood
|
2007
|
2.82
|
|
5
|
Cardiovascular involvement, an overlooked feature of Erdheim-Chester disease: report of 6 new cases and a literature review.
|
Medicine (Baltimore)
|
2004
|
2.27
|
|
6
|
Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib.
|
J Clin Oncol
|
2009
|
2.16
|
|
7
|
Blastic NK-cell lymphomas (agranular CD4+CD56+ hematodermic neoplasms): a review.
|
Am J Clin Pathol
|
2005
|
2.15
|
|
8
|
Primary cutaneous diffuse large B-cell lymphoma, leg type: clinicopathologic features and prognostic analysis in 60 cases.
|
Arch Dermatol
|
2007
|
2.00
|
|
9
|
Granulomatous mycosis fungoides and granulomatous slack skin: a multicenter study of the Cutaneous Lymphoma Histopathology Task Force Group of the European Organization For Research and Treatment of Cancer (EORTC).
|
Arch Dermatol
|
2008
|
1.78
|
|
10
|
A new device for rapid isolation by size and characterization of rare circulating tumor cells.
|
Anticancer Res
|
2011
|
1.74
|
|
11
|
Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: a prospective study of 54 patients.
|
J Am Acad Dermatol
|
2003
|
1.74
|
|
12
|
Granuloma faciale: a clinicopathologic study of 66 patients.
|
J Am Acad Dermatol
|
2005
|
1.70
|
|
13
|
Skin tumors induced by sorafenib; paradoxic RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53, and TGFBR1.
|
Clin Cancer Res
|
2011
|
1.52
|
|
14
|
WHO/EORTC classification of cutaneous lymphomas 2005: histological and molecular aspects.
|
J Cutan Pathol
|
2005
|
1.51
|
|
15
|
Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor.
|
Arch Dermatol
|
2008
|
1.49
|
|
16
|
Dermatologic symptoms associated with the multikinase inhibitor sorafenib.
|
J Am Acad Dermatol
|
2008
|
1.33
|
|
17
|
Molecular profiling of malignant peripheral nerve sheath tumors associated with neurofibromatosis type 1, based on large-scale real-time RT-PCR.
|
Mol Cancer
|
2004
|
1.19
|
|
18
|
Cytotoxic/natural killer cell cutaneous lymphomas. Report of EORTC Cutaneous Lymphoma Task Force Workshop.
|
Cancer
|
2003
|
1.15
|
|
19
|
CD56-positive haematological neoplasms of the skin: a multicentre study of the Cutaneous Lymphoma Project Group of the European Organisation for Research and Treatment of Cancer.
|
J Clin Pathol
|
2006
|
1.08
|
|
20
|
Cutaneous Destombes-Rosai-Dorfman disease: absence of detection of HHV-6 and HHV-8 in skin.
|
J Cutan Pathol
|
2002
|
1.00
|
|
21
|
Molecular profiles of neurofibromatosis type 1-associated plexiform neurofibromas: identification of a gene expression signature of poor prognosis.
|
Clin Cancer Res
|
2004
|
0.94
|
|
22
|
A new spectrum of skin toxic effects associated with the multikinase inhibitor vandetanib.
|
Arch Dermatol
|
2012
|
0.94
|
|
23
|
A collision tumor involving Basal cell carcinoma and lentigo maligna melanoma.
|
Am J Dermatopathol
|
2005
|
0.94
|
|
24
|
Bcl-2 protein expression is the strongest independent prognostic factor of survival in primary cutaneous large B-cell lymphomas.
|
Blood
|
2004
|
0.93
|
|
25
|
Comparison of histopathologic-clinical characteristics of Jessner's lymphocytic infiltration of the skin and lupus erythematosus tumidus: Multicenter study of 46 cases.
|
J Am Acad Dermatol
|
2007
|
0.93
|
|
26
|
Microarray-based identification of tenascin C and tenascin XB, genes possibly involved in tumorigenesis associated with neurofibromatosis type 1.
|
Clin Cancer Res
|
2007
|
0.93
|
|
27
|
Influence of evaluation of clinical pictures on the histopathologic diagnosis of inflammatory skin disorders.
|
J Am Acad Dermatol
|
2010
|
0.86
|
|
28
|
Value of the CD8-CD3 ratio for the diagnosis of mycosis fungoides.
|
Mod Pathol
|
2003
|
0.85
|
|
29
|
Inflammatory vitiligo-like macules that simulate hypopigmented mycosis fungoides.
|
Eur J Dermatol
|
2003
|
0.85
|
|
30
|
Characterization of CXCL13+ neoplastic t cells in cutaneous lesions of angioimmunoblastic T-cell lymphoma (AITL).
|
Am J Surg Pathol
|
2007
|
0.85
|
|
31
|
Borrelia burgdorferi-associated lymphocytoma cutis simulating a primary cutaneous large B-cell lymphoma.
|
J Am Acad Dermatol
|
2002
|
0.84
|
|
32
|
[A palpebral tumor].
|
Ann Pathol
|
2006
|
0.83
|
|
33
|
Three-Dimensional Telomeric Analysis of Isolated Circulating Tumor Cells (CTCs) Defines CTC Subpopulations.
|
Transl Oncol
|
2013
|
0.81
|
|
34
|
Different patterns of mast cells distinguish diffuse from encapsulated neurofibromas in patients with neurofibromatosis 1.
|
J Histochem Cytochem
|
2011
|
0.81
|
|
35
|
Intra-arterial angiolymphoid hyperplasia with eosinophilia.
|
J Cutan Pathol
|
2007
|
0.81
|
|
36
|
S100B and neurofibromin immunostaining and X-inactivation patterns of laser-microdissected cells indicate a multicellular origin of some NF1-associated neurofibromas.
|
J Neurosci Res
|
2011
|
0.78
|
|
37
|
Occupation and skin cancer: the results of the HELIOS-I multicenter case-control study.
|
BMC Public Health
|
2007
|
0.77
|
|
38
|
Minocycline-induced DRESS: evidence for accumulation of the culprit drug.
|
Dermatology
|
2008
|
0.76
|
|
39
|
Cell-mediated immunologic mechanism and severity of TEN.
|
Arch Dermatol
|
2005
|
0.75
|
|
40
|
[Misleading Kaposi's sarcoma: usefulness of anti HHV-8 immunostaining].
|
Ann Pathol
|
2003
|
0.75
|
|
41
|
Study of the reactive dendritic cells in small B-cell lymphoproliferations of the skin.
|
Virchows Arch
|
2007
|
0.75
|
|
42
|
[Mixed tumor or myoepithelioma of the skin? Histologic and immunohistochemical features].
|
Ann Pathol
|
2004
|
0.75
|
|
43
|
[Hematodermic CD4/CD56 neoplasm].
|
Ann Pathol
|
2004
|
0.75
|
|
44
|
Prognostic value of histologic features of toxic epidermal necrolysis.
|
J Am Acad Dermatol
|
2011
|
0.75
|